• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于达芦那韦原料药及其在市售剂型中应用的新型超高效液相色谱 - 二极管阵列检测法的开发与验证

A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form.

作者信息

Biswal Sabyasachi, Mondal Sumanta, Mondal Prasenjit

机构信息

Institute of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh, India.

Vaageswari Institute of Pharmaceutical Science, Karimnagar, Telangana, India.

出版信息

J Pharm Bioallied Sci. 2021 Jan-Mar;13(1):69-75. doi: 10.4103/jpbs.JPBS_337_19. Epub 2020 Dec 21.

DOI:10.4103/jpbs.JPBS_337_19
PMID:34084050
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8142922/
Abstract

AIMS AND OBJECTIVE

The aim of this study was to develop and validate a novel ultra-performance liquid chromatographic method for estimation of darunavir in a bulk and tablet dosage form.

MATERIALS AND METHODS

The chromatographic separation was achieved using DIKMA Endoversil (2.1mm x 50mm, 1.7 µm) column. A mixture of 40% buffer (0.1% octa sulfonic acid) and 60% acetonitrile was used as a mobile phase with the isocratic elution mode and eluent was monitored at 281nm using UV detector. The method was continued and validated in accordance with International Conference on Harmonization Guidelines. Validation study revealed the specificity and reliability of the method.

RESULTS

In this method, darunavir was eluted with retention time of 0.516 min. Calibration curve plots were found linear over the concentration ranges 10-50 μg/mL for darunavir. Limit of detection was 0.02 μg/mL and limit of quantification was found 0.07 μg/mL. The present method was also found stable in force degradation study.

CONCLUSION

The empirical evidences of all the study results revealed the suitability of the estimation of darunavir in bulk and tablet dosage form without any interference from the excipients.

摘要

目的

本研究旨在开发并验证一种用于测定原料药及片剂剂型中达芦那韦的新型超高效液相色谱法。

材料与方法

采用迪马科技的Endoversil(2.1mm×50mm,1.7μm)色谱柱进行色谱分离。以40%缓冲液(0.1%八磺酸)和60%乙腈的混合物作为流动相,采用等度洗脱模式,使用紫外检测器在281nm波长处监测洗脱液。该方法按照国际协调会议指南进行持续研究和验证。验证研究表明了该方法的特异性和可靠性。

结果

在该方法中,达芦那韦的保留时间为0.516分钟。校准曲线在达芦那韦浓度范围10 - 50μg/mL内呈线性。检测限为0.02μg/mL,定量限为0.07μg/mL。在强制降解研究中还发现本方法稳定。

结论

所有研究结果的实验证据表明,该方法适用于测定原料药及片剂剂型中的达芦那韦,且不受辅料干扰。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be8a/8142922/e5a83a3111fe/JPBS-13-69-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be8a/8142922/5c10c4d5e4e0/JPBS-13-69-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be8a/8142922/8e2e7ca40ae6/JPBS-13-69-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be8a/8142922/748051bb19a2/JPBS-13-69-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be8a/8142922/e5a83a3111fe/JPBS-13-69-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be8a/8142922/5c10c4d5e4e0/JPBS-13-69-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be8a/8142922/8e2e7ca40ae6/JPBS-13-69-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be8a/8142922/748051bb19a2/JPBS-13-69-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be8a/8142922/e5a83a3111fe/JPBS-13-69-g004.jpg

相似文献

1
A Novel Ultra Performance Liquid Chromatography-PDA Method Development and Validation for Darunavir in Bulk and Its Application to Marketed Dosage Form.一种用于达芦那韦原料药及其在市售剂型中应用的新型超高效液相色谱 - 二极管阵列检测法的开发与验证
J Pharm Bioallied Sci. 2021 Jan-Mar;13(1):69-75. doi: 10.4103/jpbs.JPBS_337_19. Epub 2020 Dec 21.
2
Stability Indicating UPLC Method Development and Validation for the Quantitative Estimation of Pazopanib in Pure form and Marketed Pharmaceutical Dosage form.用于定量评估纯品和市售药物制剂中帕唑帕尼的稳定性指示 UPLC 方法的开发和验证。
Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2024 Aug 6;40:e20240018. doi: 10.62958/j.cjap.2024.018.
3
Development and validation of an ultra performance liquid chromatography method for venlafaxine hydrochloride in bulk and capsule dosage form.盐酸文拉法辛原料药及胶囊剂型的超高效液相色谱法的开发与验证
Indian J Pharm Sci. 2010 Nov;72(6):814-8. doi: 10.4103/0250-474X.84605.
4
A Validated Reverse Phase-Ultra-Performance Liquid Chromatography Method for the Determination of Gemifloxacin Mesylate in Bulk and its Pharmaceutical Preparation.一种验证过的反相超高效液相色谱法用于测定原料药及制剂中的甲磺酸吉米沙星
Turk J Pharm Sci. 2019 Mar;16(1):8-13. doi: 10.4274/tjps.04934. Epub 2018 Dec 31.
5
Development and validation of a stability indicating RP-UPLC method for determination of quetiapine in pharmaceutical dosage form.一种用于测定药物剂型中喹硫平的稳定性指示反相超高效液相色谱法的开发与验证
Sci Pharm. 2011 Jan-Mar;79(1):97-111. doi: 10.3797/scipharm.1009-12. Epub 2011 Jan 16.
6
A New Rapid and Sensitive Stability-Indicating UPLC Assay Method for Tolterodine Tartrate: Application in Pharmaceuticals, Human Plasma and Urine Samples.一种用于酒石酸托特罗定的新型快速灵敏的稳定性指示超高效液相色谱测定方法:在药物制剂、人血浆和尿液样本中的应用。
Sci Pharm. 2012 Jan-Mar;80(1):101-14. doi: 10.3797/scipharm.1110-14. Epub 2011 Dec 5.
7
Validation and method development of Tadalafil in bulk and tablet dosage form by RP-HPLC.采用反相高效液相色谱法对他达拉非原料药及片剂剂型进行方法学验证和方法开发。
Drug Res (Stuttg). 2015 Feb;65(2):82-5. doi: 10.1055/s-0034-1372608. Epub 2014 Apr 29.
8
Development and Validation of a Rapid RP-UPLC Method for the Simultaneous Estimation of Bambuterol Hydrochloride and Montelukast Sodium from Tablets.一种用于同时测定片剂中盐酸班布特罗和孟鲁司特钠的快速反相超高效液相色谱法的开发与验证
Indian J Pharm Sci. 2012 Mar;74(2):116-21. doi: 10.4103/0250-474X.103841.
9
Analytical Method Development and Validation for the Simultaneous Estimation of Abacavir and Lamivudine by Reversed-phase High-performance Liquid Chromatography in Bulk and Tablet Dosage Forms.反相高效液相色谱法同时测定原料药和片剂剂型中阿巴卡韦和拉米夫定的分析方法开发与验证
Pharmacognosy Res. 2018 Jan-Mar;10(1):92-97. doi: 10.4103/pr.pr_96_17.
10
Reversed phase-high performance liquid chromatographic method for simultaneous estimation of tolperisone hydrochloride and etodolac in a combined fixed dose oral formulations.反相高效液相色谱法同时测定复方固定剂量口服制剂中盐酸托哌酮和依托度酸的含量
Pharm Methods. 2011 Apr;2(2):124-9. doi: 10.4103/2229-4708.84458.

引用本文的文献

1
Construction and application of highly sensitive spinel nanocrystalline zinc chromite decorated multiwalled carbon nanotube modified carbon paste electrode (ZnCrO@MWCNTs/CPE) for electrochemical determination of alogliptin benzoate in bulk and its dosage form: green chemistry assessment.用于电化学测定苯甲酸盐阿格列汀原料药及其剂型的高灵敏度尖晶石纳米晶锌铬铁矿修饰多壁碳纳米管修饰碳糊电极(ZnCrO@MWCNTs/CPE)的构建与应用:绿色化学评估
RSC Adv. 2022 Jun 30;12(30):19133-19143. doi: 10.1039/d2ra02685f. eCollection 2022 Jun 29.

本文引用的文献

1
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.《成人HIV感染治疗和预防用抗逆转录病毒药物:美国国际抗病毒学会专家组2016年建议》
JAMA. 2016 Jul 12;316(2):191-210. doi: 10.1001/jama.2016.8900.
2
Validation of simultaneous quantitative method of HIV protease inhibitors atazanavir, darunavir and ritonavir in human plasma by UPLC-MS/MS.采用超高效液相色谱-串联质谱法对人血浆中HIV蛋白酶抑制剂阿扎那韦、达芦那韦和利托那韦同时进行定量分析方法的验证。
ScientificWorldJournal. 2014 Jan 23;2014:482693. doi: 10.1155/2014/482693. eCollection 2014.
3
Computational studies of darunavir into HIV-1 protease and DMPC bilayer: necessary conditions for effective binding and the role of the flaps.
达芦那韦与 HIV-1 蛋白酶和 DMPC 双层膜的计算研究:有效结合的必要条件和瓣的作用。
J Chem Inf Model. 2012 Jun 25;52(6):1542-58. doi: 10.1021/ci300014z. Epub 2012 May 30.
4
Role of darunavir in the management of HIV infection.达芦那韦在HIV感染管理中的作用。
HIV AIDS (Auckl). 2009;1:31-9. doi: 10.2147/hiv.s5397. Epub 2009 Nov 10.
5
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.ARTEMIS研究中达芦那韦/利托那韦或洛匹那韦/利托那韦治疗失败患者的病毒学特征:96周分析
Antivir Ther. 2011;16(1):99-108. doi: 10.3851/IMP1719.
6
Combating HIV resistance - focus on darunavir.抗 HIV 耐药性 - 关注达芦那韦。
Ther Clin Risk Manag. 2008 Aug;4(4):759-66. doi: 10.2147/tcrm.s1709.
7
Darunavir: pharmacokinetics and drug interactions.达芦那韦:药代动力学与药物相互作用
Antivir Ther. 2008;13(1):1-13.
8
Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.新型蛋白酶二聚化非肽基小分子抑制剂对HIV-1复制的强效抑制作用
J Biol Chem. 2007 Sep 28;282(39):28709-28720. doi: 10.1074/jbc.M703938200. Epub 2007 Jul 17.
9
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.非肽类临床抑制剂TMC-114对具有高度耐药性突变D30N、I50V和L90M的HIV-1蛋白酶的有效性。
J Med Chem. 2006 Feb 23;49(4):1379-87. doi: 10.1021/jm050943c.
10
TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.TMC114,一种新型的1型人类免疫缺陷病毒蛋白酶抑制剂,对包括多种临床分离株在内的蛋白酶抑制剂耐药病毒具有活性。
Antimicrob Agents Chemother. 2005 Jun;49(6):2314-21. doi: 10.1128/AAC.49.6.2314-2321.2005.